Expression of p16 and p53 in non-small-cell lung cancer: Clinicopathological correlation and potential prognostic impact

Yangying Zhou, Naseruddin Höti, Minghui Ao, Zhen Zhang, Hong Zhu, Ling Li, Frederic Askin, Edward Gabrielson, Hui Zhang, Qing Kay Li

Research output: Contribution to journalArticle

Abstract

Aim: p16 and p53 are frequently altered intracellular pathways in cancers. We investigated the aberrant expression of p16 and its relationship with p53 and HPV status in primary non-small-cell lung carcinoma. Patients & methods: Lung tumor tissue microarray (n = 163), immunohistochemical study of p16 and p53, and HPV in-situ hybridization were analyzed. Results: p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). HPV was detected in 16 and 10.2% of ADC and squamous cell carcinoma. In ADCs, p16 positive tumors demonstrated a favorable median overall survival time of 60.9 months, compared with p16 negative tumors of 46.9 months (p < 0.05). Furthermore, we did not find significant relationships between p16 expression and HPV status, nor with p53 expression. Conclusion: p16 play an unique role in lung cancer survival. The mechanism of p16 needs to be further studied.

Original languageEnglish (US)
Pages (from-to)761-771
Number of pages11
JournalBiomarkers in Medicine
Volume13
Issue number9
DOIs
StatePublished - Jan 1 2019

Keywords

  • HPV
  • adenocarcinomas
  • biomarker
  • clinical survival
  • human papilloma virus
  • immunohistochemistry
  • in situ hybridization
  • non-small-cell lung carcinoma
  • p16
  • p53
  • squamous cell carcinomas

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Expression of p16 and p53 in non-small-cell lung cancer: Clinicopathological correlation and potential prognostic impact'. Together they form a unique fingerprint.

  • Cite this